Laxofalk (Macrogol 4000)

Macrogol 4000 is a high‑molecular‑weight polyethylene glycol that is poorly absorbed from the gastrointestinal tract. It exerts an osmotic effect by retaining water within the intestinal lumen, which raises stool water content, reduces stool hardness, and stimulates peristalsis. This mechanism facilitates easier passage of feces without stimulating intestinal secretions or altering electrolyte balance significantly when used as directed.

The specific dose of Laxofalk is determined by the prescribing healthcare professional based on the individual’s condition, age, and response to therapy. Patients should follow the dosage instructions provided on the product label or by their clinician and should not adjust the amount without medical advice. The prescriber sets the appropriate quantity to achieve the desired laxative effect while minimizing side effects.

Safety data for macrogol 4000 in pregnancy and lactation are limited. The product should only be used during pregnancy or while breastfeeding if the potential benefit justifies the possible risk to the fetus or infant, as assessed by a qualified healthcare provider. Women who are pregnant, planning to become pregnant, or nursing should discuss alternative options and any concerns with their physician before starting treatment.

To request Laxofalk, visit the product page on the GNH India website (gnhindia.com) and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any necessary import documentation.

Compared with stimulant laxatives, macrogol 4000 works by osmotic water retention rather than stimulating intestinal muscle contractions, which often results in a gentler, more predictable effect and a lower incidence of cramping. Unlike bulk‑forming agents, it does not rely on dietary fiber and can be used in patients with restricted diets. Its safety profile is favorable when used as directed, making it a common choice for constipation and bowel preparation.

Laxofalk should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and excessive heat. Keep the container tightly closed when not in use and store it out of reach of children. Do not expose the product to direct sunlight or damp environments, as these conditions could affect its stability and efficacy.

Laxofalk is taken orally, typically dissolved in a measured amount of water or another suitable liquid as indicated on the product label. The solution should be mixed thoroughly and consumed promptly after preparation. Patients should drink the full dose and follow any additional fluid intake recommendations from their healthcare provider to support the osmotic action of the medication.

Although rare, serious adverse events can include severe electrolyte disturbances, marked dehydration, allergic reactions such as rash or anaphylaxis, and intestinal obstruction. Patients experiencing persistent diarrhea, severe abdominal pain, swelling of the face or throat, or signs of electrolyte imbalance should discontinue use and seek immediate medical attention. Prompt recognition of these signs helps prevent complications.

Laxofalk should be avoided in individuals with known hypersensitivity to macrogol, polyethylene glycol, or any of the product’s excipients. It is also contraindicated in patients with intestinal perforation, complete bowel obstruction, or severe inflammatory bowel disease. Persons with significant renal impairment should use the product only under medical supervision, and children should only use formulations specifically approved for pediatric use.